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This study investigated the temporal relationship between cardiomyopathy and renal pathology in the type II diabetic
Zucker diabetic fatty (ZDF) rat. We hypothesized that changes in renal function will precede the development of cardiac
dysfunction in the ZDF rat. Animals (10 weeks old) were divided into four experimental groups: Lean Control (fa/?) LC
(n = 7), untreated ZDF rats (n = 7) sacrificed at 16 weeks of age, and LC (n = 7) untreated ZDF rats (n = 9) sacrificed at
36 weeks of age. LV structural/functional parameters were assessed via Millar conductance catheter. Renal function was
evaluated via markers of proteinuria and evidence of hydronephrosis. LV mass was significantly less in the ZDF groups at
both time points compared to age-matched LC. End diastolic volume was increased by 16% at 16 weeks and by 37% at 36
weeks of age (p < 0.05 vs. LC). End diastolic pressure and end systolic volume were significantly increased (42% and 27%
respectively) at 36 weeks of age in the ZDF compared to LC. Kidney weights were significantly increased at both 16 and
36 week in ZDF animals (p < 0.05 vs. LC). Increased urinary albumin and decreased urinary creatinine were paralleled by
a marked progression in the severity of hydronephrosis from 16 to 36 weeks of age in the ZDF group. In summary, there
is evidence of progressive structural and functional changes in both the heart and kidney, starting as early as 16 weeks,
without evidence that one pathology precedes or causes the other in the ZDF model of type II diabetes.

Introduction
Several European epidemiologic studies reveal the catastrophic and interrelated complications of cardiorenal failure
in the diabetic population (DREAM,1 LIRICO,2 HOPE3 and
FRAMINGHAM4). However, in the United States the clinical
manifestation and significance of the combined effects of cardiovascular and renal disease remain underappreciated. Currently,
the number of diabetics in the United States is estimated at 23.4
million people or 7.8% of entire population.5,6 Despite the numerous pathologies associated with type II diabetes, nearly 2/3rds of
all diabetic patients die of heart failure.7 However, the contribution of renal dysfunction to the onset of myocardial dysfunction
in diabetes, independent of ischemic disease, remains unknown.
Numerous studies investigating the effects of Type II diabetes on the heart have used the Zucker diabetic fatty (ZDF)
rat model.8 Likewise, investigators examining diabetes-induced
nephropathy have also employed the ZDF rat.9 Although there
is an association between decreased renal function and increased
cardiovascular morbidity/mortality,10,11 few studies have examined the correlative onset of each of these disease states and the
impact they have on the overall progression of pathologic changes
in individual organ systems.12,13 Moreover, the time points

selected in various separate studies on the heart and kidney in
diabetic rats differ significantly, which further confounds the
ability to determine the relationship between these pathologies.
To address the temporal relationship between renal and cardiovascular pathology in diabetes, this study examines left ventricular (LV) remodeling and systolic/diastolic functional parameters
and renal morphology and function in the same animals at two
time points, 16 and 36 weeks of age. These time points were chosen as they best correspond to the early (14–17 weeks of age) and
later stage (24–37 weeks of age) ranges of animal ages used in
previous studies, focused on either cardiac or renal pathophysiology.13-18 We hypothesize the ZDF animal model of type II diabetes will display systolic and diastolic dysfunction at the earlier
time point prior to development of renal pathology. Whereas we
believe there will be significant loss of systolic and diastolic ventricular function at 36 weeks of age, which corresponds to the
severity of renal pathology.
Results
Comparison of body and LV weights between lean control and
ZDF rats. By 16 weeks of age ZDF animals weighed significantly more than their age-matched LC group. However, at 36
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Table 1. Comparison of whole body, LV and kidney weights in LC and ZDF rats at 16 and 36 weeks of age
Body weight
(gm)

LV weight
(mg)

Left kidney weight
(mg)

Right kidney weight
(mg)

Blood glucose
(mg/dl)

Lean Control

329 ± 25

917 ± 47

1300 ± 95

1296 ± 64

105 ± 15

ZDF

413 ± 31*

850 ± 50*

1939 ± 109*

1960 ± 250*

545 ± 52*

16 weeks of age

36 weeks of age
Lean Control

456 ± 11

920 ± 32

1271 ± 94

1282 ± 85

105 ± 7

ZDF

358 ± 39*

796 ± 80*

1864 ± 84*

1933 ± 222*

392 ± 29*

All values are reported as mean ± SD. *denotes p ≤ 0.05 compared to age-matched LC rats.
Table 2. Comparison of in vivo left ventricular functional parameters in lean control (LC) and zucker diabetic fatty (ZDF) rats at 16 and 36 weeks
of age
Heart
rate
(bpm)

End
systolic
pressure
(mmHg)

End
diastolic
pressure
(mmHg)

End
systolic
volume
(µl)

End
diastolic
volume
(µl)

Cardiac
output
(ml/min)

Stroke
volume
(µl)

Volume
@ Min &
Max
dP/dt (µl)

Min & Max
dV/dt
(µl/sec)

Lean Control

282 ± 10

121 ± 3

9±1

196 ± 22

306 ± 23

31 ± 5

110 ± 16

206 ± 25
301 ± 24

-2134 ± 400
2778 ± 330

ZDF

282 ± 35

117 ± 16

10 ± 1

200 ± 13

355 ± 4*

44 ± 7

155 ± 16*

227 ± 17
364 ± 19*

-2268 ± 372
3251 ± 284

Lean Control

265 ± 10

124 ± 5

7±1

299 ± 16

367 ± 12

36 ± 3

138 ± 13

238 ± 19
350 ± 12

-3267 ± 200
3750 ± 540

ZDF

235 ± 10

125 ± 8

10 ± 1*

380 ± 34*

504 ± 34*

29 ± 2

123 ± 5

394 ± 35*
497 ± 35*

-2643 ± 325*
2819 ± 260*

16 weeks of
age

36 weeks of
age

Values are presented as mean ± SEM. *denotes p < 0.05 versus age-matched LC rats. n ≥ 6 per group. dP/dt = an indicator of myocardial contractility (maximum or minimum first derivative of LV pressure) dV/dt max = left ventricular ejection rate during systole, and dV/dtmin = peak rate of passive
diastolic filling of the left ventricle.

weeks there was a marked reduction of body weight in the ZDF
group (Table 1). Blood glucose was significantly elevated in the
ZDF group compared to LC at both 16 and 36 weeks of age.
LV mass was significantly decreased in the ZDF groups at both
time points compared to age matched LC. These trends were also
evident when normalized to tibial lengths.
Left ventricular morphology and functional assessment.
Table 2 details ventricular structural and functional parameters
for all groups. Mean arterial blood pressure was not significantly
different between ZDF and LC at 16 weeks of age (113 ± 11 vs.
102 ± 4 mmHg; ZDF vs. LC) or at 36 weeks of age (108 ± 6 mm
vs. 113 ± 5 Hg; ZDF vs. LC respectively). End diastolic volume
(EDV) in ZDF rats was increased by 16% at 16 weeks and
increased by 37% at 36 weeks of age relative to age-matched
LC. The change in chamber volume was mirrored by a significant increase in end diastolic pressure (EDP) (42% increase) at
36 weeks of age which was not seen at 16 weeks. Additionally,
at 36 weeks end systolic volume (ESV) was markedly increased
(27%) compared to age matched LC, but, again, this change in
ESV was not evident at 16 weeks of age. No difference in heart
rate or cardiac output was evident between any of the groups;
however stroke volume which was significantly increased in
the 16 week ZDF group was no longer different between ZDF
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and LC at 36 weeks (Table 2). The fact that stroke volume was
increased at the earlier, but not the later time point, is significant as this could indicate that the intrinsic stretch response of
the heart (Frank-Starling) was an adaptational response while
the ventricle continued to remodel. Ejection fraction which was
43% at 16 weeks decreased to 24% in the 36 week ZDF group.
Overall, these results indicate that there was progressive dilatation of the LV chamber.
Neither maximum nor minimum first derivative of LV
pressure (dP/dt; an indicator of myocardial contractility) was
different between groups at either time point. The maximum and
minimum first derivative of LV volume (dV/dtmax = left ventricular ejection rate during systole, and dV/dtmin = peak rate of passive
diastolic filling of the left ventricle, respectively) were higher in
the 16-week-old ZDF versus LC. There was a significant increase
in maximal and minimal dV/dt between 36-week-old ZDF and
age-matched LC hearts (Table 2). Additionally, there was a trend
(p = 0.09) toward an increase in optimal volume for maximum
dP/dt (Vol@dP/dt max) in the ZDF group at 16 weeks; this
increase became statistically significant at 36 weeks compared to
LC (p ≤ 0.05). These changes in volume @ dP/dt suggest that in
order to maintain contractility the heart has adapted to optimize
actin and myosin filament overlap enabling more cross bridge
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formation during contraction. Lastly, we analyzed the time constant of LV pressure decay, Tau, as a measurement of LV relaxation according to Weisfeldt et al.19,20 Tau was increased in the
ZDF group at both 16 and 36 weeks, compared to age-matched
LC groups (22 ± 1 vs. 13 ± 0.4 msec, p ≤ 0.01, at 16 weeks; and
16 ± 0.5 vs. 13 ± 0.5 msec, p ≤ 0.05, at 36 weeks). Collectively,
these overall changes in LV chamber morphology and function
are characteristic of diastolic cardiomyopathy in diabetic patients,
and also of diastolic heart failure which is an emerging clinical
manifestation in heart failure patients.
Renal structural and functional assessment. As shown in
Table 1, both left and right kidney weights were appreciably
increased in the ZDF group, compared to LC, as early as 16
weeks of age. At 36 weeks kidney weights were still significantly
increased above age-matched LC but not different from values
seen at 16 weeks. Water intake was increased by six-fold at 16
weeks and remained elevated at 36 weeks of age in ZDF rats relative to LC. Urine output in the ZDF group was increased eightFigure 1. Comparison of 24 hour urine output in Lean Control and
Zucker diabetic fatty (ZDF) rat kidneys at 10, 16, 24 and 36 weeks of age.
fold as early as 10 weeks of age (Fig. 1). By 16 weeks urine output
Urine output is significantly increased in ZDF animals as early as 10 weeks
was elevated 20-fold above LC and remained at this level at 36
of age and remains markedly increased at all time points relative to lean
weeks of age. Figure 2 illustrates the morphological changes in
controls.Values are mean ± SD. *denotes p ≤ 0.01 versus age matched lean
the kidneys from ZDF animals. Of these animals, 14% showed
control.
signs of moderate levels of hydronephrosis at 16 weeks of age (Table
3). At 36 weeks of age, evidence of
a shift to mostly mild to moderate
hydronephrosis was also apparent
in the lean control group. However,
the 36-week-old ZDF group exhibited predominately moderate to
severe signs of hydronephrosis
(Table 3, Fig. 2). Hyperfiltration
caused by diabetes induced vasodilatation may significantly contribFigure 2. Representative images of hydronephrosis in Lean Control (LC) and Zucker diabetic fatty (ZDF)
ute to the progression of this form
rats at 16 and 36 weeks of age. Kidneys were cut across the cross-sectional axis of the hillar region. Eviof obstructive uropathy in the ZDF
dence of progression of morphologic changes is seen in both LC and ZDF kidneys from 16 to 36 weeks of
rat.21
age with hydronephrosis being more severe in the diabetic animals.
Excretion of urinary albumin
was unchanged at 16 weeks, relaTable 3. Scoring and distribution of hydronephrosis in lean control
tive to controls, but was markedly increased at 24 weeks and
(LC) and zucker diabetic fatty (ZDF) rat kidneys at 16 and 36 weeks of
progressed further at 36 weeks (Fig. 3). Urinary creatinine
age
levels were also significantly decreased at all time points
Lean
ZDF
Lean
ZDF
relative to LC purportedly because of urine dilution. The ratio
control
control
of urinary albumin to creatinine, an indicator of microalbu16 weeks
16 weeks 36 weeks
36 weeks
minuria, remained constant in the lean control animals, but
of age
of age
of age
of age
increased significantly in ZDF rats as early as 10 weeks of age,
Normal
5 (71)
1 (14)
0 (0)
0 (0)
and significantly increased further between 10 and 36 weeks
Mild
2 (29)
5 (71)
2 (28)
1 (10)
in ZDF rats (Table 4). Lastly, we performed correlation analyModerate
0
1 (14)
5 (77)
6 (60)
sis by linear regression between cardiac parameters (e.g., volSevere
0
0
0
(0)
3
(30)
ume and function) and renal function parameters. Significant
correlation was found in the 36 week old ZDF group between
Briefly, kidney sections were assigned a value of either; (0) minimal or
no spacing between the papilla and calyx, (1) definitive but mild calyceal
urinary albumin and stroke work (r2 value = 0.94, p = 0.02).
spacing with normal papillary shape, (2) calyceal dilatation and compresMoreover, urinary creatinine was positively correlated with
sion of the papilla, and (3) extreme distension of the calyx, compaction
2
cardiac output in the 36 weeks old ZDF group (r value = 0.67,
of the lateral cortex and severe papillary dilatation. Values are presented
p = 0.04).
as frequency with percent of total animals in parentheses.
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Figure 3. Temporal course of 24 hour urinary
excretion of albumin from Lean Control (LC)
& Zucker diabetic fatty (ZDF) rat kidneys at
10, 16, 24 and 36 weeks of age. Excretion of
urinary albumin was unchanged at 10 or 16
weeks of age, relative to LC, but was markedly
increased at 24 weeks and progressed further
at 36 weeks relative to LC as well as the 10
and 16 weeks of age values in the same animals.
Values are mean ± SD. *denotes p ≤ 0.01 versus
age matched lean control. †p ≤ 0.01 versus 10
weeks of age ZDF. #p < 0.05 vs. 24 weeks of
age ZDF.

Table 4. Urinary excretion of creatinine and albumin by LC & ZDF rats
at 10, 16, 24 and 36 weeks of age

Lean
Control

10
weeks

16
weeks

24
weeks

36 weeks

8.3 ± 0.5

10.5 ±
0.5

11.7 ± 0.6

12.8 ± 1.4

42 ± 16

47 ± 3

31 ± 1

41 ± 7

2.1 ± 0.3*

1.7 ± 0.3*

1.6 ± 0.1*

1.3 ± 0.1*

143 ± 31*

350 ±
39*

620 ±
74* †

865 ±
245* †

Albumin/
Creatinine
Ratio
ZDF
Albumin/
Creatinine
Ratio

Values are mean ± SEM. *denotes p ≤ 0.01 versus age matched lean
control. †p < 0.05 versus 10 weeks of age.

Discussion
Guyton’s model of cardiorenal syndrome illustrates the pathophysiologic interconnection between the heart and kidney organ
systems.22 Due to the interrelated nature of their function,
changes in one system (cardiovascular) can catalyze changes in
the other (renal) which lead to an adverse feedback cycle involving
neurohormonal, systemic and local inflammatory mechanisms.
However, the point at which the collective effects of ventricular and renal dysfunction becomes greater than their individual
pathologies remains to be elucidated. Clinical studies demonstrate a strong link between symptomatic heart failure and renal
dysfunction, but raise questions as to which is the true secondary
illness.11 A recent study by Marsh et al.12 reported altered diastolic
relaxation as well as the presence of hydronephrosis in the ZDF
rat at 14 weeks of age. On the other hand, work by Fredersdorf
et al.23 investigating insulin’s affect on myocardial morphology
and function in non insulin dependent diabetes concluded that
at 19 weeks of age the ZDF rat exhibited LV hypertrophy and
enhanced contractility as assessed by echocardiography. Schafer
et al.13 also showed that at 37 weeks of age both glomerulosclerosis and proteinuria were present in the ZDF rat. However, in
that study, only heart rate and minimum first derivative of LV
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pressure (minimum and maximum dP/dt) were decreased in
ZDF animals compared to LC, whereas multiple indices of LV
systolic function and compliance were not significantly different.
Because of the limited amount of simultaneous/parallel information on the development of diabetic cardiomyopathy and renal
pathology, we sought to investigate the kinetics of development
of changes in left ventricular and renal morphology and function
in an animal model of type II diabetes.
Left ventricular morphology and functional assessment. We
observed that significant changes in LV chamber morphology
occurred in the untreated ZDF animals as a diabetes-induced
adaptation to maintain overall function. Specifically, type II diabetic rats had significantly increased left ventricular end systolic
and end diastolic volume(s) compared to LC animals as early as
16 weeks of age. Stroke volume was also significantly increased
at the same time. Additionally, the rate of volume change in the
LV as indicated by minimum and maximum first derivative of
LV volume (dV/dt) was also elevated in the 16-week-old ZDF
versus age-matched LC. These findings are consistent with the
previous findings by Fredersdorf et al.23 which demonstrated that
at 19 weeks of age the ZDF rat exhibited enhanced contractility.
Ultimately, the response of the heart is to maintain cardiac output
and thus preserve mean arterial pressure. Initially in other forms
of heart failure, the stretch of the myocytes due to end diastolic
volume (also known as preload) seeks to maximize overlap potential for actin and myosin filaments within the existing sarcomeres
a phenomenon known as the Frank-Starling mechanism. By this
means, renal blood flow and glomerular filtration rate would supposedly be able to maintain normal physiologic function at the
16 weeks of age endpoint as increased systolic blood pressure in
this model is associated with renal injury.24,25 Chronically, dilatation of the LV chamber allows the heart to maintain cardiac
output by adding sarcomeres (contractile units) in a parallel or in
series fashion to the preexisting sarcomeres. Eventually, a point
is reached where the ability of the heart to further compensate is
exhausted and the contractile force of the muscle becomes ineffective and heart begins to fail.26,27 At this stage, ventricular mass
is no longer increased relative to the enlargement of the chamber volume which is what we observed at the 36 weeks of age
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time point. However, in this model of type II diabetes it remains
uncertain as to whether this is an adaptational response to worsening cardiac function or expansion of blood volume due to renal
impairment as suggested by others.28,29
The difference in LV mass in ZDF rats, compared to LC, is
an interesting observation. Indeed, changes in LV mass and or
geometry greatly affect the overall function of the heart, and
are typically a progressive response to chronic physiologic stress
such as alterations in cardiac output due to altered hemodynamic
load on the heart.30 Although overt hypertension was not evident in these animals (Table 2), wall stiffening (as indicated
by increased Tau), which commonly occurs in diabetic cardiomyopathy, would necessitate chamber dilation. Regardless of
etiology (i.e., volume overload, pressure overload or myocardial
injury) persistent elevation in ventricular wall stress initiates cardiac remodeling that results in; (1) initial ventricular dilatation
to maintain stroke volume and thus cardiac output, (2) subsequent cardiac dysfunction due to excessive remodeling, and (3)
ultimately decompensated heart failure.31 Recent clinical studies
on left ventricular hypertrophy (LVH) in type II diabetes, based
on echocardiography, indicate that there are also a significant
number of normotensive individuals which do not present with
indication(s) of LVH.32-34 The untreated ZDF animals appear to
be similar to this clinical phenotype in which there is limited (or
inadequate) hypertrophy.
Renal morphology and function. The progression of proteinuria in the Zucker diabetic fatty rat has been documented
before,17,35-37 but without parallel studies on cardiac function.
Recent studies by Bickel et al.38,39 as well as Maddox and coworkers40 found that, even with the presence of mild changes in glomerular morphology in 24-week-old ZDF animals, there was no
difference in creatinine clearance, compared to age-matched lean
controls. The albumin to creatinine ratio, an indicator of microalbuminuria, was significantly different after 24 weeks of age. The
association between microalbuminuria and cardiovascular risk is
well established, however only recently has it been recognized as
having predictive value of heart failure.11 Although we did not
measure glomerular filtration, we did observe moderate to severe
hydronephrosis at 36 weeks in ZDF animals. Previous studies
have detailed similar findings of hydronephrosis in the ZDF
rat,12,41 however, the underlying etiology remains uncertain. Since
both the LC and ZDF animals presented with this pathology,
the leptin receptor deficiency is probably not the cause. However,
Marsh et al.12 postulated an epigenetic cause as a potential
underlying heritable mechanism behind hydronephrosis in these
animals. Recent work by El Osta et al.42 demonstrated that temporary hyperglycemia induced persistent epigenetic changes in
the promoter of the nuclear factor kappaB (subunit p65 NFκB)
which lasted for at least 6 days under subsequent normoglycemic
conditions. While the ZDF rat is only one of many models of
diabetes, this same phenomenon of hydronephrosis also occurs in
the KKay transgenic mouse model of type II diabetes.43
Renal and cardiovascular function in diabetes. While our
findings indicate that EDV for the 16 week old ZDF animals
was markedly increased, similar to the findings of Marsh et al.12
this occurred prior to significant changes in proteinuria or the
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presence of significant hydronephrosis. However, the albumin/
creatinine ratio was increased at both 10 and 16 weeks in the
ZDF animal (Table 4). The changes in LV chamber morphology
and altered myocardial relaxation (Tau) as early as 16 weeks in
association with evidence of renal impairment suggest that diabetes induced cardiac and renal pathophysiology may develop in
parallel with one another in the ZDF animal.
Nevertheless, only 20% of diabetics with microalbuminuria
progress to nephropathy and only 20% of those individuals will
progress to end stage renal disease 20 years after onset of nephropathy.7 In contrast to renal complications, diabetics have a 1.4-fold
higher chance of developing congestive heart failure.44 It should
be recognized that renal pathology may not be apparent until
it is fairly severe, e.g., only after loss of 80–90% of functional
nephrons. Measurement of urinary glucose is not a good diagnostic indicator of diabetes because glucose does not appear in urine
until the renal threshold is exceeded. Similarly changes in albuminuria and creatininemia probably become apparent only after
significant loss of renal function. Renal disease may be silent, but
just as harsh as cardiovascular pathology; the latter may just be
more easily detected. However, it is clinically evident that once
the “functional reserve” of the kidney has been exhausted there is
a compounding affect that severely impacts survival.45
Materials and Methods
Experimental design. All Animal Use Protocols were approved
by the Institutional Animal Care and Use Committee (IACUC)
and conform with the Guide for the Care and Use of Laboratory
Animals, published by the US National Institutes of Health (NIH
Publication no. 85-23, revised 1996). The Zucker Diabetic Fatty
rats (ZDF) rat is an inbred leptin receptor-deficient model of
adult onset type II diabetes displaying insulin resistance, hyperinsulinemia and hyperglycemia. Male ZDF (fa/fa) and lean control heterozygous litter mates (LC; fa/?) were obtained at 6 weeks
of age (~200 g) from Charles River Laboratories (Wilmington,
MA). All animals were maintained on Purina 5008 rat chow with
water ad libitum. Animals were housed two to a cage in a 12:12-h
dark/light cycle controlled room. At the age of 10 weeks, after
confirming hyperglycemia via tail vein blood samples, the animals were divided into two experimental groups: (1) lean control
rats (LC; n = 7) and untreated ZDF rats (n = 7) sacrificed at 16
weeks of age, and (2) lean control rats (LC; n = 7) and untreated
ZDF rats (n = 9) sacrificed at 36 weeks of age. These time points
were chosen as they best correspond to the early (14–17 weeks of
age) and later stage (24–37 weeks of age) ranges of animal ages
used in previous studies, focused on either cardiac14-16,23,46 or renal
pathophysiology.13,17,18,36,41,47 Prior to sacrifice, left ventricular systolic and diastolic structural and functional parameters were
assessed; plasma samples were collected, the heart and kidneys
were removed, rinsed in ice cold PBS and weighed, and then portions were either snap frozen in liquid nitrogen for biochemical
analysis or placed in Telley’s fixative for histological analysis.
Left ventricular functional assessment. As previously
described, LV systolic and diastolic pressure and volume functional analysis was performed in anesthetized rats using a high-
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fidelity Millar pressure/volume (SPR-838; Millar Instruments,
Houston, TX) conductance catheter inserted into the LV via the
right carotid artery.48-50 For calibration, this measurement technique requires that a small amount (0.1 ml) of 15% saline be
introduced into the blood volume of the anesthetized animal at
the end of the experimental protocol as a correction factor for the
blood-LV tissue interface. Data were analyzed using PVAN 3.5
software from Millar Instruments.
Assessment of renal structural and functional changes. The
right kidney was cut along a sagital plane in the hilar region and
fixed by immersion in Telley’s fixative. Following staining with
hematoxylin and eosin, hydronephrosis was calculated by criteria
previously described.12,41 Briefly, kidney sections were assigned a
value of either; (0) minimal or no spacing between the papilla
and calyx, (1) definitive but mild calyceal spacing with normal
papillary shape, (2) calyceal dilatation and compression of the
papilla, and (3) extreme distension of the calyx, compaction of
the lateral cortex and severe papillary dilatation.
Urinary measurements. Animals were individually housed
in metabolic cages for measurement of twenty-four hour water
intake and urine production. Urine samples were stored at -80°C
until assayed for urinary albumin using an ELISA assay (Cayman
Chemicals, Ann Arbor, MI) and urinary creatinine by a colorimetric kit assay based on the Jaffe reaction (Bio-Rad, Hercules,
CA). From these measurements, the albumin to creatinine ratio
was determined.
Statistics. Statistical analyses were performed with Graphpad
5.0 software (Prism Inc., San Diego, CA). All grouped data
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